Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05953337 · ClinicalTrials.gov registry record · NA
Radioembolization Trial Utilizing Eye90 Microspheres™ for the Treatment of Hepatocellular Carcinoma (HCC)
A NA study of Hepatocellular Carcinoma and Liver Cancer, sponsored by ABK Biomedical.
- Active
- Registry status
- NA
- Development phase
- 120
- Enrollment target
- 20
- Study locations
NCT05953337: Active NA study of Hepatocellular Carcinoma and Liver Cancer, sponsored by ABK Biomedical.
NCT05953337 is a NA study of Hepatocellular Carcinoma and Liver Cancer that is active but no longer recruiting, run by ABK Biomedical. The registered enrollment target is 120 participants, below the 257-participant average among 145 other Hepatocellular Carcinoma trials with a reported enrollment target (53% lower). The trial reports 20 study locations across 16 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05953337, a NA study of Hepatocellular Carcinoma and Liver Cancer, is active but no longer recruiting, sponsored by ABK Biomedical.
- ACTIVE NOT RECRUITING
- Registry status
- NA
- Development phase
- 120 participants
- Enrollment target
- 20
- Study locations
Study Summary
This is a prospective, multi-center, open-label study to evaluate the effectiveness and safety of Eye90 microspheres® in the treatment of subjects with unresectable Hepatocellular Carcinoma (HCC). Eye90 microspheres is a medical device containing yttrium-90 (Y-90), a radioactive material, and provides local radiation brachytherapy for the treatment of liver tumors.
Primary Outcome
The percentage of subjects with ORR using local mRECIST, as assessed by independent panel review.
Conditions Studied
Interventions
- DEVICE EYE90 Microspheres Treatment
Study Locations (20)
Florida
- AdventHealth Radiation Oncology at Altamonte Springs - Altamonte Springs
- Miami Cardiac and Vascular Institute at Baptist Hospital Miami - Miami
Georgia
- Emory University Hospital Midtown - Atlanta
- Piedmont Hospital - Atlanta
Illinois
- Northwestern University Memorial Hospital - Chicago
- University of Illinois Hospital and Health Sciences System - Chicago
Missouri
- University of Missouri - Ellis Fischel Cancer Center - Columbia
- SSM Health Saint Louis University - St Louis
Arizona
- The University of Arizona Cancer Center - Tucson
California
- University of California - Irvine - Orange
Iowa
- University of Iowa Health Care - Iowa City
Kentucky
- University of Louisville - Louisville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 120 participants |
| Start Date | 2023-09-21 |
| Est. Completion | 2027-02 |
| Phase | NA |
What the registry record for NCT05953337 still lists
NCT05953337 is an interventional study that assigns participants to a tested intervention. The registered 120 participants enrollment target is mid-sized for trials with a published cap, below the 257-participant average among 145 other Hepatocellular Carcinoma trials with a reported enrollment target (53% lower).
The record links to 3 conditions, with Hepatocellular Carcinoma appearing as the primary indexed condition, and to 1 intervention - of which EYE90 Microspheres Treatment is the first listed.
NCT05953337 names 20 study sites across 16 states, led by Florida, Georgia, Illinois.
Frequently Asked Questions
What is clinical trial NCT05953337 about?
NCT05953337 is a clinical study titled "Radioembolization Trial Utilizing Eye90 Microspheres™ for the Treatment of Hepatocellular Carcinoma (HCC)". This is a prospective, multi-center, open-label study to evaluate the effectiveness and safety of Eye90 microspheres® in the treatment of subjects with unresectable Hepatocellular Carcinoma (HCC). Eye90 microspheres is a medical device containing yttrium-90 (Y-90), a radioactive material, and provid...
What is the current status of trial NCT05953337?
This trial is currently active not recruiting. It is a NA study. The enrollment target is 120 participants. The study started on 2023-09-21. Estimated completion is 2027-02.
What conditions does trial NCT05953337 study?
This clinical trial studies the following conditions: Hepatocellular Carcinoma, Liver Cancer, Hepatocellular Carcinoma Non-resectable.
What interventions are being tested in trial NCT05953337?
The interventions under investigation include: EYE90 Microspheres Treatment (DEVICE).
Who is sponsoring clinical trial NCT05953337?
This trial is sponsored by ABK Biomedical, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05953337 being conducted?
This trial has 20 study locations across Arizona, California, Florida, Georgia, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hepatocellular Carcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05953337's enrollment target sits among peer trials
120 52nd of 145 higher than 93 of 145 other Hepatocellular Carcinoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Hepatocellular Carcinoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Targeted Navigation in Hepatocellular Carcinoma (HCC)
RECRUITING · NA
-
Y90 Radioembolization Dose Delivery and Radiation Exposure Assessment
RECRUITING · NA
-
HepQuant: Study to Assess the Role of Blood-based Biomarkers and Quantitative MR Imaging for Patients Receiving Radiation Therapy for Liver Cancer
RECRUITING · NA
-
Pilot Comparing ctDNA IDV vs. SPV Sample in Pts Undergoing Biopsies for Hepatobiliary and Pancreatic Cancers
RECRUITING · NA
-
Psychoeducational Intervention for Patients With Hepatocellular Carcinoma
RECRUITING · NA
-
CEUS vs. AMRI for HCC Detection in Patients With Indeterminate Liver Nodules
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01174108 · 120 participants · Phase 2
Allogeneic Hematopoietic Stem Cell Transplantation for Severe Aplastic Anemia and Other Bone Marrow Failure Syndromes Using G-CSF Mobilized CD34+ Selected Hematopoietic Precursor Cells Co-Infused With a Reduced Dose of Non-Mobilized Donor T-cells
- NCT01627301 · 120 participants · NA
Sympathetic Overactivity in Post-traumatic Stress Disorder
- NCT02025023 · 120 participants · Phase 3
Local 5-Fluorouracil Injection for the Treatment of Chalazia: A Prospective, Comparative Study
- NCT02128906 · 120 participants · Phase 2
Radiotherapy With Cisplatin vs. Docetaxel-cetuximab in HNSCC: ERCC1 Biomarker Enrichment and Interaction Design
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI